Key result
Acute myeloid leukemia patients receiving chemotherapy had significantly higher cardiac-specific mortality compared to the general population, with a standardized mortality ratio of 6.35.
Why the study?
AML is treated with anthracycline-containing regimens with known cardiotoxicity, but cardiac-specific mortality in AML patients receiving chemotherapy remains unknown.
Does chemotherapy increase cardiac-specific mortality in patients with acute myeloid leukemia compared to the general population?
Observational (n=64,679)
Yes
Does chemotherapy increase cardiac-specific mortality in patients with acute myeloid leukemia compared to the general population?
AML patients receiving chemotherapy have a 6.35-fold higher risk of cardiac-specific death compared to the general population, highlighting the need for long-term cardiovascular surveillance in this population.
Answers are grounded in this paper and cite their sources.
Supports closer cardiac surveillance in AML chemotherapy survivors; extends anthracycline cardiotoxicity data but remains hypothesis-generating.
Background: Acute myeloid leukemia (AML) is a common hematological malignancy treated with regimens containing anthracycline, an agent with cardiotoxicity. However, the cardiac-specific mortality in AML patients receiving chemotherapy remains unknown. Methods: In this population-based study, patients diagnosed with AML between 1973 and 2015 were identified in the Surveillance, Epidemiology, and End Results database. Cumulative mortality by cause of death was calculated. To quantify the excessive cardiac-specific death compared with the general population, standardized mortality ratios (SMRs) were calculated. Multivariate Cox regression analyses were performed to identify risk factors associated with cardiac-specific death and AML-specific death. Results: A total of 64,679 AML patients were identified between 1973 and 2015; 68.48% of patients (44,292) received chemotherapy. Among all possible competing causes of death, AML was associated with the highest cumulative mortality. The AML patients who received chemotherapy showed excessive cardiac-specific mortality compared with the general population, with an SMR of 6.35 (95% CI: 5.89-6.82). Age, year of diagnosis, sex, and marital status were independently associated with patient prognosis. Conclusion: Cardiac-specific mortality in AML patients receiving chemotherapy is higher than that in the general population.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted an observational in Acute myeloid leukemia (n=64,679). Chemotherapy vs. General population was evaluated on Cardiac-specific mortality (SMR 6.35, 95% CI 5.89-6.82, p=< 0.0001). Acute myeloid leukemia patients receiving chemotherapy had significantly higher cardiac-specific mortality compared to the general population, with a standardized mortality ratio of 6.35.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: